Brenmiller Energy Ltd Dossier - Source-backed chat

Brenmiller Energy Ltd

BNRGNASDAQ

SectorIndustrials

IndustryElectrical Components & Equipment

Beta (adjusted)-0.07

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.46Price as of 13 Aug 2026

Data confidenceNot applicable

Market Cap $1.5M

Enterprise Value $1.8M

Shares Outstanding 408.8K diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Brenmiller Energy Ltd. is transitioning from a technology developer to a commercial-stage provider of thermal energy storage (TES) solutions. The company achieved a major milestone in 2025 by recognizing its first commercial TES system revenue of $387,000 from its flagship 32 MWh Tempo project. While the launch of the BNRG360 integrated heat-and-power strategy and a projected revenue increase to $1.7 million in 2026 provide a visible growth bridge, Brenmiller remains in a heavy investment phase. With a net loss of $13.9 million in 2025 and a high cash burn rate, the company is highly dependent on dilutive equity financing, primarily through its ongoing securities purchase agreement with Alpha Capital Anstalt. Consequently, a Hold recommendation is warranted until commercial execution scales sufficiently to reduce reliance on external capital.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Commissioning delays at the Tempo or Wolfson Medical Center projects defer revenue recognition. The company fails to secure additional non-dilutive capital, leading to heavy dilution from the conversion of preferred shares and exercise of warrants at reset prices, depressing the stock price further.

Base CaseCentral scenario

The company successfully completes commissioning of the Tempo project, realizing the projected $1.7 million in revenue for 2026. The BNRG360 strategy gains traction with industrial customers, leading to new project agreements in Europe and Italy (via the INNOVA cooperation agreement). Funding from the Alpha Capital SPA continues to support working capital, but ongoing dilution limits substantial per-share upside.

Bull CaseUpside scenario

Brenmiller is transitioning from a pure-play thermal energy storage equipment provider to an integrated industrial energy platform developer (BrenX strategy). This shift is designed to capture recurring, project-level cash flows and improve project economics. The company's proprietary bGen technology is highly relevant to the massive global industrial decarbonization market, and its strategic partnerships (such as with INNOVA in Italy) expand its commercial footprint.

Scenarios reflect our research view at the research date.

Key Investment Merits

First commercial revenue recognized in 2025, validating the commercial viability of the proprietary bGen™ TES technology.
Transition to the BNRG360 integrated energy platform, which bundles heat and power under long-term contracts to improve project economics and bankability.
Strong pipeline of global opportunities valued at over $500 million, supported by strategic cooperation agreements such as the June 2026 framework with INNOVA in Italy.

Key Investment Risks

Severe liquidity constraints and high cash burn, with a net loss of $13.9 million against $4.9 million in cash at the end of 2025.
Significant risk of equity dilution due to full-ratchet anti-dilution provisions in outstanding warrants and preferred shares issued to Alpha Capital Anstalt.
Concentration of near-term revenue on a limited number of flagship projects (Tempo and Wolfson Medical Center).

Thesis Invalidation Triggers

Failure to complete the commissioning and validation phases of the Tempo project.
Inability to access remaining tranches of the $25 million Alpha Capital SPA or other financing sources, leading to a going-concern crisis.
A prolonged delay in the execution of the Wolfson Medical Center project or European utility deployments.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.